PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Gesamtlänge aller Episoden: 9 days 15 hours 55 minutes
Immunotherapy for Advanced Urothelial Carcinoma: Translating the Evidence to Canadian Clinical Practice
Visit https://www.peervoice.com/QUX860 to view the entire programme with slides.
Learning From the Literature: New Data for Improving CF Management and Patient Outcomes
Visit https://www.peervoice.com/VNQ860 to view the entire programme with slides.
Managing Major Depressive Disorder: How a Landmark Study of Antidepressants Can Assist Your Clinical Decision-Making Process
Visit https://www.peervoice.com/ZRC860 to view the entire programme with slides.
A New Era in HIV Treatment: The Role of Novel Fixed-Dose Combination Regimens in Canadian Practice
Visit https://www.peervoice.com/SBG860 to view the entire programme with slides.
Conversations on Steps to Biologic Therapy for Atopic Dermatitis: Patient and Dermatologist Insights for European Practice
Visit https://www.peervoice.com/UVW860 to view the entire programme with slides.
Stepping Up Atopic Dermatitis Management: Considering the Latest Canadian Recommendations
Visit https://www.peervoice.com/TGV860 to view the entire programme with slides.
To Switch or Not to Switch? Using Asparaginase Activity Testing to Optimize Pediatric ALL Outcomes
Visit https://www.peervoice.com/SAF860 to view the entire programme with slides.
Floppy Baby Syndrome: Is it a Treatable Neuromuscular Disease?
Floppy Baby Syndrome: Is it a Treatable Neuromuscular Disease?
Exploring Treatment Choices in Crohn’s Disease: Using Current Evidence to Optimize Outcomes
Visit https://www.peervoice.com/PUW860 to view the entire programme with slides.
Newer Targeted Therapies for Rheumatoid Arthritis: Weighing the Pros and Cons
Newer Targeted Therapies for Rheumatoid Arthritis: Weighing the Pros and Cons